DMN:FRA
Diamyd Medical AB
€0.076
arrow_upward
+7.91%(+0.0056) 1D
Hun 26, 10:00:00 PM GMT+2 · EUR
search
Lahat ng simbolo
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa DMN...
Buksan
€0.08
Mataas
€0.08
Mababa
€0.08
Mkt. cap
156.03M
Avg. na dami
133.00
Dami
0.00
Mataas nang 52-wk
€1.80
Mababa nang 52-wk
€0.05
Bilang ng mga empleyado
41
Buksan
€0.08
Mataas
€0.08
Mababa
€0.08
Mkt. cap
156.03M
Avg. na dami
133.00
Dami
0.00
Mataas nang 52-wk
€1.80
Mababa nang 52-wk
€0.05
Bilang ng mga empleyado
41
Mga balita at kwento
Mula sa mga source sa buong web
www.marketscreener.com
·
17 minuto ang nakalipas
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000 Growth Benchmark
CNBC
·
19 minuto ang nakalipas
CNBC Daily Open: Another weekend escalation in Iran, another market shrug
Simply Wall Street
·
31 minuto ang nakalipas
Does Royalty Pharma’s (RPRX) Index Upgrade Signal Deeper Defensive Strength In Its Business Model?
Yahoo Finance
·
3 oras ang nakalipas
Stock market today: S&P 500, Nasdaq, Dow futures climb as a halt to US-Iranian attacks is called
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Tungkol sa Diamyd Medical AB
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa